Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Following Through On Breakthrough: What’s Next For FDASIA Success?

This article was originally published in RPM Report

Executive Summary

FDA is building a case for enhanced funding to support the “Breakthrough” therapy program and at the same time is working to educate sponsors on how to use the new program effectively. The 21st Century Cures process floated a proposal for a new “Breakthrough” approval pathway – though that idea has been dropped. Still, it sets up an interesting discussion heading into 2017.

You may also be interested in...



First Draft FDA User Fee Bill Is Squeaky Clean

House and Senate release discussion draft of user fee reauthorization legislation that does not include any additional policy or practice changes for US FDA, though they may arrive later.

First Draft FDA User Fee Bill Is Squeaky Clean

House and Senate release discussion draft of user fee reauthorization legislation that does not include any additional policy or practice changes for US FDA, though they may arrive later.

FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds

User fees won't support dedicated staff, but rather FTEs that will work on the popular program as needed.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel